XERS vs AMRX

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus 8. 0% for Amneal Pharmaceuticals, Inc. (AMRX). Amneal Pharmaceuticals, Inc. (AMRX) offers the better valuation at 62. 4x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amneal Pharmaceuticals, Inc.

(AMRX) is the cheapest at 62. 4x versus Xeris Biopharma Holdings, Inc. at 2071. 9x. On forward P/E, Amneal Pharmaceuticals, Inc. is actually cheaper at 13. 8x.

Over the past 5 years, Amneal Pharmaceuticals, Inc.

(AMRX) delivered a total return of +163. 8%, compared to +104. 0% for Xeris Biopharma Holdings, Inc. (XERS). Over 10 years, the gap is even starker: AMRX returned -54. 9% versus XERS's -67. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xeris Biopharma Holdings, Inc.

(XERS) is the lower-risk stock at 1. 04β versus Amneal Pharmaceuticals, Inc. 's 1. 17β — meaning AMRX is approximately 13% more volatile than XERS relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus 8. 0% for Amneal Pharmaceuticals, Inc. (AMRX). On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc. grew EPS 157. 9% year-over-year, compared to 100. 9% for Xeris Biopharma Holdings, Inc.. Over a 3-year CAGR, XERS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amneal Pharmaceuticals, Inc.

(AMRX) is the more profitable company, earning 2. 4% net margin versus 0. 2% for Xeris Biopharma Holdings, Inc. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XERS leads at 8. 5% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — XERS leads at 81. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amneal Pharmaceuticals, Inc.

(AMRX) trades at 13. 8x forward P/E versus 55. 3x for Xeris Biopharma Holdings, Inc. — 41. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XERS: 35. 7% to $9. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04)). Both have compounded well over 10 years (XERS: -67. 2%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XERS is a small-cap high-growth stock; AMRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.